Recent advances in bladder cancer chemotherapy

Cancer Investigation

Volumn 19, Issue 1, 2001, Pages 77-85

  Vaughn, D J ^a   Malkowicz, S B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PACLITAXEL; PROTEIN P53; TAXANE DERIVATIVE; TUMOR MARKER; VINBLASTINE;

ADVANCED CANCER; ANEMIA; AREA UNDER THE CURVE; BLADDER CARCINOMA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CLINICAL TRIAL; CYSTOSCOPY; GRANULOCYTOPENIA; HUMAN; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TRANSITIONAL CELL CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; HUMANS; NEOADJUVANT THERAPY; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS; TAXOIDS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0035087092     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-100000078     Document Type: Review

References (56)

1. Cancer statistics, 1999
2. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: Efficacy and patterns of response and relapse
3. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study
4. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors
5. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium
6. A phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin plus human granulocyte-macrophage colony stimulating factor in patients with advanced transitional cell carcinoma
7. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial carcinoma
8. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced bladder carcinoma: An eastern cooperative oncology group trial
9. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: Results of a randomized trial
10. M-VAC in transitional cell carcinoma (TCC): Prognostic factors and long-term survival in 203 patients (pts)
11. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study
12. The activity of antimicrotubular agents in human bladder cancer cell lines
13. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: A phase II trial of the eastern cooperative oncology group (E1892)
14. Carboplatin-based chemotherapy for bladder cancer
15. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
16. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: An active and tolerable outpatient regimen
17. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma
18. Paclitaxel plus carboplatin in patients with metastatic urothelial cancer: Results of a phase II trial
19. Phase II study of taxol (Paclitaxel) and carboplatin in patients with advanced transitional cell carcinoma of the urothelium: Preliminary results
20. Carboplatin and paclitaxel (Carbo/Tax) for advanced transitional cell carcinoma (TCC) of the urothelium
21. E2895 cisplatin and paclitaxel in advanced carcinoma of the urothelium: A phase II trial of the eastern cooperative oncology group (ECOG)
22. Phase II trial of paclitaxel and cisplatin in advanced urothelial cancer (UC)
23. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: A phase II trial
24. Ifosfamide + paclitaxel + cisplatin (ITP) chemotherapy for patients (pts) with unresectable or metastatic transitional cell carcinoma (TCC)
25. Phase I evaluation of sequential doxorubicin + gemcitabine (AG) then ifosfamide + paclitaxel + cisplatin (ITP) for patients (pts) with unresectable or metastatic transitional cell carcinoma (TCC)
26. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma
27. Docetaxel (Taxotere): An active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients
28. Docetaxel and cisplatin in metastatic urothelial cancer: A phase II study
29. Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer
30. Weekly gemcitabine in advanced bladder cancer: A preliminary report from phase I study
31. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum
32. Phase II study of single agent gemcitabine in previously untreated patients with metastatic urothelial cancer
33. Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer
34. A phase II study of gemcitabine and cisplatin in patients with transitional cell carcinoma (TCC) of the urothelium
35. Gemcitabine (G) + cisplatin (C): An active regimen in advanced transitional cell carcinoma (TCC)
36. Gemcitabine (gem) plus cisplatin (CDDP) in metastatic transitional cell carcinoma (TCC): Final results of a phase II study
37. A phase I trial of gemcitabine plus paclitaxel combination therapy in patients with refractory solid tumors
38. A phase II trial of paclitaxel, cisplatin, and gemcitabine (TCG) in patients (Pts) with advanced transitional cell carcinoma (TCC) of the urothelium
39. Phase II evaluation of carboplatin, paclitaxel, and gemcitabine in advanced urothelial carcinoma
40. Role of adjuvant chemotherapy in the treatment of bladder cancer
41. Urothelial carcinoma: Adjuvant and neoadjuvant chemotherapy
42. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: A prospective comparative trial
43. Radical cystectomy with or without adjuvant polychemotherapy for non-organ confined transitional cell carcinoma of the urinary bladder: Prognostic impact of lymph node involvement
44. Neoadjuvant CMV chemotherapy and cystectomy or radiation in muscle-invasive bladder cancer: First analysis of MRC/EORTC intercontinental trial
45. Prognostic markers in bladder cancer: A contemporary review of the literature
46. Implications of the p53 tumor-suppressor gene in clinical oncology
47. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer
48. Comparison of p53 protein overexpression with p53 mutation in bladder cancer: Clinical and biological aspects
49. Accumulation of nuclear p53 and tumor progression in bladder cancer
50. Over-expression of the p53 nuclear oncoprotein in transitional cell carcinoma of the bladder and its prognostic value
51. WAF1, a potential mediator of p53 tumor suppression
52. Induction of WAF1/CIP1 by a p53-independent pathway
53. Effect of p21 (WAF1/CIP1) expression on tumor progression in bladder cancer
54. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC
55. P53 and treatment of bladder cancer
56. Evaluation of prognostic markers in urinary bladder cancer using tumor tissue arrays